Tandem Diabetes Care (TNDM) to Release Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) will post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Tandem Diabetes Care to post earnings of ($0.80) per share for the quarter. Tandem Diabetes Care has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Trading Up 0.4 %

TNDM stock opened at $35.12 on Thursday. Tandem Diabetes Care has a 52 week low of $13.82 and a 52 week high of $40.74. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The company’s 50-day simple moving average is $30.51 and its 200 day simple moving average is $25.18. The company has a market capitalization of $2.27 billion, a PE ratio of -10.21 and a beta of 1.12.

Analyst Upgrades and Downgrades

TNDM has been the topic of a number of analyst reports. Citigroup increased their price target on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus raised their target price on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday. Finally, StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Friday, April 19th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, Tandem Diabetes Care presently has an average rating of “Hold” and an average price target of $37.27.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.